0LIF.L - Ultragenyx Pharmaceutical Inc.
| Previous close | 48.78 |
| Open | 48.51 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 48.51 - 48.51 |
| 52-week range | 33.90 - 65.68 |
| Volume | |
| Avg. volume | 265 |
| Market cap | 28.257M |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.87 |
| Earnings date | 26 Jul 2023 - 31 Jul 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksUltragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
ZacksUltragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
ZacksUltragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.
ZacksDrug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others
Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.
ZacksUltragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
ZacksUltragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.
ZacksUltragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y
Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.
ZacksUltragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksCRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics AG (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksUltragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.
ZacksUltragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksGilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksUltragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Ultragenyx Pharmaceutical Stock Is Cratering Today
Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.
ZacksUltragenyx (RARE) Provides Update From Angelman Syndrome Study
Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.